Supplementary Online Content
|
|
|
- Robert Lamb
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. Published online October 13, doi: /jamaoncol etable 1. Concepts and Terms Defining Prostate Cancer and Alzheimer Disease in Clinical Text Analysis etable 2. Variable ICD-9 Diagnostic Codes etable 3. Gleason Score Distribution in Available Patients (n=4360) etable 4. Traditional Multivariable Cox Proportional Hazards Regression for the Association of Androgen Deprivation Therapy With Negative Controls eappendix. Medication Names Queried to Identify Individuals on Androgen Deprivation Therapy efigure. Kaplan-Meier Curves Examining the Age-Stratified Cumulative Probability of Remaining Dementia Free in the Unmatched Cohort
2 etable 1. Concepts and Terms Defining Prostate Cancer and Alzheimer Disease in Clinical Text Analysis String Drug/Event Concept Unique Identifier dementia Dementia C alzheimer's disease Dementia C alzheimer disease Dementia C alzheimer's dementia Dementia C vascular dementia Dementia C frontotermporal dementia Dementia C senile dementia Dementia C alzheimer dementia Dementia C multi-infarct dementia Dementia C disease, alzheimer Dementia C dementias Dementia C multiinfarct dementia Dementia C disease, alzheimer's Dementia C dementia nos Dementia C pick disease Dementia C vascular dementia, uncomplicated Dementia C semantic dementia Dementia C dementia in alzheimer's disease Dementia C multi infarct dementia Dementia C pick's disease Dementia C alzheimer type dementia Dementia C senile dementia uncomp Dementia C early onset alzheimer disease Dementia C dementia, vascular Dementia C dementia, nos Dementia C dementia, alzheimer type Dementia C dementia, unspecified Dementia C unspecified dementia Dementia C presenile dementia Dementia C senile dementia with delirium Dementia C binswanger's disease Dementia C frontotemporal dementias Dementia C dementia, multiinfarct Dementia C dementia alzheimer's type Dementia C vascular dementia with delirium Dementia C dementia in conditions classified elsewhere Dementia C senile dementia, uncomplicated Dementia C frontotemporal lobe dementia Dementia C
3 String Drug/Event Concept Unique Identifier dementia, senile Dementia C dementia, multi-infarct Dementia C subcortical leukoencephalopathy Dementia C dementia vascular Dementia C late onset alzheimer disease Dementia C picks disease Dementia C alzheimer's disease with early onset Dementia C senile dementia, alzheimer type Dementia C dementia in alzheimer's disease with early onset Dementia C binswanger's dementia Dementia C subcortical vascular dementia Dementia C dementia, semantic Dementia C senile dementia with paranoia Dementia C senile delusion Dementia C binswanger disease Dementia C alzheimer disease, late onset Dementia C pre-senile dementia Dementia C alzheimers dis Dementia C multi-infarct, dementia Dementia C vascular dementias Dementia C disease, pick Dementia C vascular dementia with depressed mood Dementia C dementia, frontotemporal Dementia C multi-infarct dementias Dementia C alzheimer disease, early onset Dementia C chronic progressive subcortical encephalopathy Dementia C dementia, multi infarct Dementia C disease, pick's Dementia C multi-infarct dementia with delirium Dementia C dementia in conditions ec Dementia C dementia, presenile Dementia C dementia in alzheimer's disease with late onset Dementia C dementia due to pick's disease Dementia C dementia multi-infarct Dementia C senile dementia nos Dementia C alzheimer's disease with late onset Dementia C adenocarcinoma of prostate Prostate Cancer C adenocarcinoma of the prostate Prostate Cancer C ca - cancer of prostate Prostate Cancer C ca prostate Prostate Cancer C
4 cancer of prostate Prostate Cancer C String Drug/Event Concept Unique Identifier cancer of the prostate Prostate Cancer C cancer, prostate Prostate Cancer C cancer, prostatic Prostate Cancer C cancers, prostate Prostate Cancer C carcinoma of prostate Prostate Cancer C carcinoma of the prostate Prostate Cancer C carcinoma prostate Prostate Cancer C carcinoma prostatic Prostate Cancer C ductal adenocarcinoma of the prostate Prostate Cancer C embryonal rhabdomyosarcoma of the prostate Prostate Cancer C endometrioid carcinoma of the prostate Prostate Cancer C hormone refractory prostate cancer Prostate Cancer C hormone-refractory prostate cancer Prostate Cancer C leiomyosarcoma of prostate Prostate Cancer C leiomyosarcoma of the prostate Prostate Cancer C malignant neoplasm of prostate Prostate Cancer C malignant neoplasm of the prostate Prostate Cancer C metastatic prostate cancer Prostate Cancer C metastatic prostate carcinoma Prostate Cancer C neuroendocrine tumor of the prostate Prostate Cancer C pn0 prostate cancer Prostate Cancer C pn1 prostate cancer Prostate Cancer C prostate adenocarcinoma Prostate Cancer C prostate cancer Prostate Cancer C prostate cancer metastatic Prostate Cancer C prostate cancer recurrent Prostate Cancer C prostate cancer stage i Prostate Cancer C prostate cancer stage ii Prostate Cancer C prostate cancer stage iv Prostate Cancer C prostate cancers Prostate Cancer C prostate carcinoma Prostate Cancer C prostate carcinoma metastatic Prostate Cancer C prostate ductal adenocarcinoma Prostate Cancer C prostate embryonal rhabdomyosarcoma Prostate Cancer C prostate rhabdomyosarcoma Prostate Cancer C prostate sarcoma Prostate Cancer C prostatic cancer Prostate Cancer C prostatic cancer metastatic Prostate Cancer C prostatic cancers Prostate Cancer C
5 prostatic carcinoma Prostate Cancer C pt2 prostate cancer Prostate Cancer C String Drug/Event Concept Unique Identifier pt2a prostate cancer Prostate Cancer C pt2b prostate cancer Prostate Cancer C pt2c carcinoma of prostate Prostate Cancer C pt2c prostate cancer Prostate Cancer C pt3 prostate cancer Prostate Cancer C pt3b prostate cancer Prostate Cancer C recurrent cancer of the prostate Prostate Cancer C recurrent prostate cancer Prostate Cancer C recurrent prostate carcinoma Prostate Cancer C rhabdomyosarcoma of prostate Prostate Cancer C rhabdomyosarcoma of the prostate Prostate Cancer C sarcoma of prostate Prostate Cancer C sarcoma of the prostate Prostate Cancer C small cell carcinoma of the prostate Prostate Cancer C stage i prostate cancer Prostate Cancer C stage ii prostate cancer Prostate Cancer C stage iii prostate cancer Prostate Cancer C stage iv prostate cancer Prostate Cancer C
6 etable 2. Variable ICD-9 diagnostic Codes Term ICD-9 code(s) CPT code(s) Prostate cancer 185 Radical prostatectomy , Dementia , or Cardiovascular disease 443.9, 440.2, 428, 413, 414 (excluding 414.1x), 412, 411, 410; 410 and 412 if prior to prostate cancer diagnosis Diabetes 250; 357.2; X; Stroke 430, 431, 432, 433, 434, 436 Malignancy ; 174; 175; ;
7 etable 3. Gleason Score Distribution in Available Patients (n=4360) Gleason score n % % % % 6 2, % 7 1, % % % %
8 etable 4. Traditional Multivariable Cox Proportional Hazards Regression for the Association of Androgen Deprivation Therapy with Negative Controls Outcome HR (95% CI) P Value n* Tuberculosis 1.55 ( ) Allergic rhinitis 1.32 ( ) Abdominal aortic aneurysm 1.00 ( ) HR, Hazard ratio; CI, confidence interval Adjusted for age, race, smoking status, anti-coagulant, anti-platelet, anti-hypertensive and statin therapy, and history of cardiovascular disease, diabetes, stroke or malignancy *Number of relevant failure events
9 eappendix. Medication Names Queried to Identify Individuals on Androgen Deprivation Therapy Leuprolide, goserelin, triptorelin, histrelin, Degarelix, flutamide, bicalutamide, nilutamide, Enzalutamide, Cyproterone acetate, Lupron, Zoladex, Trelstar, Vantas, Firmagon, Eulexin, Casodex, Nilandron, Xtandi, Nizoral, Androcur, Eligard, Cyprostat, Anandron, Flutamin, Cytomid, Cosudex, Calutide, Kalumid
10 efigure. Kaplan-Meier Curves Examining the Age-Stratified Cumulative Probability of Remaining Dementia Free in the Unmatched Cohort Non-ADT users < 70 years, n=4,844; ADT users < 70 years, n=925; Non-ADT users 70 years, n=2,602; ADT users 70 years, n=901. Each curve was independently statistically significantly different from all other curves (P < 0.05) ADT, Androgen deprivation therapy.
Clinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
Clinical Policy: Enzalutamide (Xtandi) Reference Number: CP.CPA.203 Effective Date: Last Review Date: 02.19
Clinical Policy: (Xtandi) Reference Number: CP.CPA.203 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer
Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer www.nshealth.ca Hormone Therapy for Prostate Cancer What is the prostate? The prostate is one of the male sex glands. It makes seminal fluid
ERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
Prostate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
Metastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
C. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
In autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
Androgen Deprivation Therapy (ADT) Following Recurring Prostate Cancer Or When Androgen Deprivation Becomes The Necessary Therapy
Androgen Deprivation Therapy (ADT) Following Recurring Prostate Cancer Or When Androgen Deprivation Becomes The Necessary Therapy By Prostate Cancer Patient and Activist/Mentor Charles (Chuck) Maack with
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
Supplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
Hormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
Supplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
NCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
SAMPLE ONLY. Your Health Matters. Advanced Prostate Cancer and its Treatment A Patient Guide. Please order from Documents and Media: 415/
Your Health Matters Advanced Prostate Cancer and its Treatment A Patient Guide UCSF Genitourinary Medical Oncology Program Charles Ryan, MD, UCSF Patient Advocates Please order from Documents and Media:
Medication Prior Authorization Form
Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
Report on New Patented Drugs Trelstar LA
Report on New Patented Drugs Trelstar LA Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
Androgen Deprivation Therapy Its impact and the nursing role. Jane Thacker Uro-Oncology Nurse Specialist
Androgen Deprivation Therapy Its impact and the nursing role Jane Thacker Uro-Oncology Nurse Specialist Overview of content To gain an understanding of ADT (androgendeprivation therapy) and why and how
Supplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
Medical code list: possible Alzheimer's disease Read Code Read Term E Senile and presenile organic psychotic conditions E00..
Medical code list: possible Alzheimer's disease E00..00 Senile and presenile organic psychotic conditions E00..11 Senile dementia E00..12 Senile/presenile dementia E000.00 Uncomplicated senile dementia
Coding clean-up Exercise Guidance to GPs to improve dementia coding, and raise diagnosis rates. A step by step approach
Coding clean-up Exercise Guidance to GPs to improve coding, and raise diagnosis rates Introduction: why is this important? A step by step approach Achieving timely diagnosis of is a major national priority,
Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
Definition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
Radiation Therapy. External Beam Radiation Therapy
Radiation Therapy Radiation therapy is a non-invasive treatment for prostate cancer that uses x-rays or gamma-rays to eradicate prostate cancer cells. There are several forms of radiation therapy that
Uncorrected Author Proof
Journal of Alzheimer s Disease Reports xx (20xx) x xx DOI 10.3233/ADR-180052 IOS Press 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 No Relationship of Anti-Androgens
Supplementary Online Content
Supplementary Online Content Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solidorgan transplantation in Ontario, Canada. JAMA Oncol. Published online January 7, 2016. doi:10.1001/jamaoncol.2015.5137
Specialty Mapping Guides ICD-9 to ICD-10
Specialty Mapping Guides ICD-9 to ICD-10 The conversions contained within this crosswalk were the most current version at the time of development. All efforts should be made by the attendee to stay current
Initial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
reviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
Supplementary Online Content
Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online
Updates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer
B88 April 2015 2.1 Community Interest Company Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer This bulletin focuses on luteinising hormone-releasing hormone (LHRH) agonists. Currently
Mr PHIP No. 5 Hormone treatment for prostate cancer
Mr PHIP No. 5 Hormone treatment for prostate cancer Mr Phip Hormone treatment controls cancer growth by reducing the effects of male hormones. Mr Phip No. 5 / Key points cancer cells require male hormone
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
Initial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
To treat or not to treat: When to treat! A case presentation
To treat or not to treat: When to treat! A case presentation Filip Ameye, MD,Phd Universitary Hospitals Leuven, Belgium Departement of Urology Prostate Center A case presentation Pt. 76 y. Mild LUTS (07/1999)
Crosswalk File of ICD9 Diagnosis Codes to Risk Group Assignment 1-Apr-15
1 1500 MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS 1 1501 MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS 1 1502 MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS 1 1503 MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS 1
Management of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
Prostate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
Supplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
Prostate Cancer: Hormone treatment. Information for patients, families and friends
Prostate Cancer: Hormone treatment Information for patients, families and friends About this booklet This booklet is designed to give you information about hormone treatment for prostate cancer and what
Supplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
American Medical Association, American Academy of Neurology Institute and American Psychiatric Association (2016)
Source(s) American Medical Association, American Academy of Neurology Institute and American Psychiatric Association (2016) Measure Domain Communication and Care Coordination: Process Brief Abstract Description
Response to Concerns of NQF Neurology Steering Committee
November 30, 2012 6312 Old Keene Mill Court Springfield, VA 22152 Phone: 703-690-1987: www.pqaalliance.org Fax: 703-690-1756 To: National Quality Forum From: David Nau, PhD, RPh, CPHQ, FAPhA Senior Director,
Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
National Audit of Dementia Round 4 (2018) Sampling guidance for the Casenote Audit
National Audit of Dementia Round 4 (2018) Sampling guidance for the Casenote Audit March 2018 HQIP 2018 Timeline for data collection The data collection period will be staggered as shown below. This is
2017 American Medical Association. All rights reserved.
Supplementary Online Content Borocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3
The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol
Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been
Supplementary Online Content
Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
Introduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
Supplementary Online Content
Supplementary Online Content Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes:
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within
Volume 11; Number 5 February 2017 REVIEW OF GONADOTROPIN RELEASING HORMONE AGONISTS FOR PROSTATE CANCER (REVISED EDITION)
Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust Volume 11;
Francesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0037-9 September 2014, Vol. 13, No. 9, P417 P421 Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer* Abeer
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
Supplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
Supplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
Supplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
Supplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
Treatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
PROSTATE CANCER. What is Prostate Cancer?
1 Medical Topics - Prostate Cancer PROSTATE CANCER What is Prostate Cancer? Prostate cancer is cancer that occurs in a man's prostate a small walnut-shaped gland that produces the seminal fluid that nourishes
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
Advanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
January Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic
When radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
Please consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
Overview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
SYNOPSIS PROTOCOL AFU-GETUG 20/0310
SYNOPSIS PROTOCOL AFU-GETUG 20/0310 A) IDENTIFICATION OF THE CLINICAL TRIAL SPONSOR CODE NUMBER: AFU-GETUG 20/0310 VERSION AND DATE: VERSION DATED MAY, 05 TH 2011 TITLE OF TRIAL: Phase III randomised trial
On-line Table 1: Dementia diagnoses and related ICD codes for the diagnostic groups a
On-line Table 1: diagnoses and related ICD codes for the diagnostic groups a Diagnosis (N = 1504) ICD Code Patients Scanned with 3T; SWI (%) Subjective cognitive impairment (n 385) Z03.2A, Z03.3, and R41.8A
Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
Dendritic Cell Based Cancer Vaccine Development
Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM
2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
ICD-10-CM Diagnosis Code. C61 is a billable/specific ICD-10-CM code that. Metastasis from malignant tumor of prostate; Prostate
1-10-2017 2018 ICD-10-CM Diagnosis Code. C61 is a billable/specific ICD-10-CM code that. Metastasis from malignant tumor of prostate; Prostate cancer. Diagnosis Code C61 information,. ICD-10 Diagnosis
Supplementary Online Content
Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic
QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
Supplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
Drug Class Monograph
Drug Class Monograph Class: Gonadotropin Releasing Hormone (GnRH) Analogs Drugs: Eligard (leuprolide acetate), Firmagon (degarelix), Lupaneta Pack (leuprolide acetate and norethindrone), Lupron Depot (leuprolide
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
Correspondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
Prostate cancer that is detected early when it's still confined to the prostate gland has a better chance of successful treatment.
Diseases and Conditions Prostate cancer By Mayo Clinic Staff Prostate cancer is cancer that occurs in a man's prostate a small walnut shaped gland that produces the seminal fluid that nourishes and transports
Icd 10 code pancreatic cancer
Free, official coding info for 2018 ICD - 10 -CM C25.9 - includes detailed rules, notes, synonyms, ICD -9-CM conversion, index and annotation crosswalks, DRG grouping and. Free, official coding info for
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
Definitions of chronic conditions used to define the number of serious comorbidities in the study.
Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x
Supplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
Chapter 8 Malignant Disease and Immunosuppression
Chapter 8 page number 1 Chapter 8 Malignant Disease and Immunosuppression First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions)
ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT?
ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT? Igor Tsaur University Medicine Mainz COI Urologische Klinik und Poliklinik Off-label use of drugs, devices, or other agents: